Articles

Crizotinib Receives Expanded FDA-Approval to Treat Patients with Rare NSCLC

FDA Updates, In the News

Crizotinib (Xalkori) has been approved for expanded use in patients with metastatic non−small-cell lung cancer (NSCLC) whose tumors have an ROS1 gene alteration, according to an announcement by the US Food and Drug Administration (FDA). The first and only approved treatment for this patient population, crizotinib blocks ROS1 protein activity in tumors, possibly preventing NSCLC from spreading. Read More ›

FDA Expands Use of Xalkori to Treat Rare Form of Advanced Non-Small Cell Lung Cancer

FDA Updates, In the News

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Read More ›

Oral Therapies for Multiple Myeloma Continuum

Oral Therapies for Multiple Myeloma Continuum

From 2004 to 2013, 22 new oral anticancer medications were introduced in the United States, which is almost the same number (27) of oral anticancer medications that were introduced in the previous 50 years combined. Of the US Food and Drug Administration (FDA)-approved myeloma novel therapies, 5 are orally administered. With the FDA approval of ixazomib (Ninlaro; a first-in-class oral proteasome inhibitor) in November 2015, an all-oral treatment combination for patients with myeloma is now a reality with the combination of ixazomib, lenalidomide (Revlimid), and dexamethasone (Decadron) Read More ›

Clinical Challenge

FDA Approves Bridion to Reverse Effects of Neuromuscular Blocking Drugs Used During Surgery

Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner. Read More ›

Incorporating Oral Therapy Compliance into the Routine of Patients with Myeloma

By Cindy Chmielewski, Patient Advocate and Mentor

Hematologic Cancers

Oral oncolytics represent 25% to 35% of the drugs in the oncology pipeline.1 They are patient friendly, allow patients to manage their treatment, and overall, have a less disruptive effect on patient's everyday lives. Read More ›

Taking a Closer Look at Inflammation and Symptoms in Patients with Myelofibrosis

By Leslie Wyatt

Hematologic Cancers

Great advances have been made in our understanding of how myeloproliferative neoplasms (MPNs)-essential thrombocythemia, polycythemia vera, myelofibrosis (MF)-result in overproduction of inflammatory markers, according to Holly L. Geyer, MD, Assistant Professor of Medicine, Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ, and colleagues. Read More ›

How to Communicate with Patients with Myeloma to Achieve the Best Outcomes

By Deborah Christensen, RN, BSN, HNB-BC, Oncology Nurse Navigator, Dixie Regional Medical Center, St. George, UT

Hematologic Cancers

Treating cancer with oral medications that are taken at home sounds like a great idea, and it is, once adherence barriers are addressed. Read More ›

A New Era of Oral Therapies for Multiple Myeloma Implementing routines and strategies to promote adherence

By Sabby Muneer, PhD

Hematologic Cancers

Recent advancements in the treatment of multiple myeloma (MM) have led to significant improvements in patient outcomes, including unprecedented survival rates. Read More ›

Early Intervention of Inflammation May Be Key in Myeloproliferative Neoplasms

By E. K. Charles, MBS

Hematologic Cancers

With recent evidence pointing to a link between chronic inflammation and Philadelphia-negative myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, and myelofibrosis, Hans Carl Hasselbalch, MD, DMSc, and Mads Emil Bjorn, MD, PhDc, Department of Hematology, Roskilde Hospital, University of Copenhagen, Denmark, recently published a review article purporting that myeloproliferative neoplasms are inflammatory diseases. Read More ›

Page 204 of 376

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.